Skip to main content
Erschienen in: Der Radiologe 2/2017

27.01.2017 | Kolorektales Karzinom | Leitthema

Lebermetastasen kolorektaler Karzinome

verfasst von: Prof. Dr. R.‑T. Hoffmann, MBA, EBIR

Erschienen in: Die Radiologie | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Lebermetastasen des kolorektalen Karzinoms sind die häufigste Todesursache bei dieser Tumorerkrankung. Aktuell wird die chirurgische Resektion als Goldstandard und als einzig potenziell kuratives Verfahren gesehen. Allerdings sind lediglich ca. 25 % der Patienten bei Diagnosestellung resektabel. Aus diesem Grund wurden in den letzten Jahren verschiedene interventionell onkologische Verfahren entwickelt, die zur Behandlung von Lebermetastasen eingesetzt werden können. Ziel der interventionell onkologischen Verfahren ist es, entweder mit lokal-ablativen Techniken lokal begrenzte Metastasen ebenfalls potenziell kurativ zu behandeln, mit transarteriellen Verfahren unresektable Tumoren entweder chirurgisch oder lokalablativ angehbar zu machen oder eine Verlängerung des Überlebens in einer palliativen Situation zu erreichen. Zu diesen Techniken zählen transarterielle Therapien wie die Chemo- oder Radioembolisation sowie eine Vielzahl unterschiedlicher Ablationsverfahren wie Radiofrequenz-, Mikrowellenablation oder die irreversible Elektroporation (IRE).
In diesem Artikel werden die Indikationen der einzelnen Verfahren, deren Ergebnisse und diese im Vergleich zu chirurgischen Verfahren anhand der aktuellen Literaturlage beleuchtet.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed
2.
Zurück zum Zitat Pathak S, Poston GJ (2010) Colorectal liver metastases; the current scenario. Indian J Surg Oncol 1(4):350–355CrossRefPubMed Pathak S, Poston GJ (2010) Colorectal liver metastases; the current scenario. Indian J Surg Oncol 1(4):350–355CrossRefPubMed
3.
Zurück zum Zitat Poston GJ (2004) Surgical strategies for colorectal liver metastases. Surg Oncol 13(2–3):125–136CrossRefPubMed Poston GJ (2004) Surgical strategies for colorectal liver metastases. Surg Oncol 13(2–3):125–136CrossRefPubMed
4.
Zurück zum Zitat Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13(5):668–676CrossRefPubMed Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13(5):668–676CrossRefPubMed
5.
Zurück zum Zitat Gallagher DJ, Kemeny N (2010) Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78(3–4):237–248CrossRefPubMed Gallagher DJ, Kemeny N (2010) Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78(3–4):237–248CrossRefPubMed
6.
Zurück zum Zitat Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA (2006) Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1261–1268CrossRefPubMed Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA (2006) Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1261–1268CrossRefPubMed
7.
Zurück zum Zitat Xing M, Kooby DA, El-Rayes BF, Kokabi N, Camacho JC, Kim HS (2014) Locoregional therapies for metastatic colorectal carcinoma to the liver – an evidence-based review. J Surg Oncol 110(2):182–196CrossRefPubMed Xing M, Kooby DA, El-Rayes BF, Kokabi N, Camacho JC, Kim HS (2014) Locoregional therapies for metastatic colorectal carcinoma to the liver – an evidence-based review. J Surg Oncol 110(2):182–196CrossRefPubMed
8.
Zurück zum Zitat Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontieres meeting 2013. Eur Radiol 25(12):3438–3454CrossRefPubMedPubMedCentral Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontieres meeting 2013. Eur Radiol 25(12):3438–3454CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat McGahan JP, Browning PD, Brock JM, Tesluk H (1990) Hepatic ablation using radiofrequency electrocautery. Invest Radiol 25(3):267–270CrossRefPubMed McGahan JP, Browning PD, Brock JM, Tesluk H (1990) Hepatic ablation using radiofrequency electrocautery. Invest Radiol 25(3):267–270CrossRefPubMed
10.
Zurück zum Zitat Goldberg SN, Gazelle GS (2001) Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 48(38):359–367PubMed Goldberg SN, Gazelle GS (2001) Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 48(38):359–367PubMed
11.
Zurück zum Zitat Groeschl RT, Pilgrim CH, Hanna EM et al (2014) Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 259(6):1195–1200CrossRefPubMed Groeschl RT, Pilgrim CH, Hanna EM et al (2014) Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 259(6):1195–1200CrossRefPubMed
13.
Zurück zum Zitat Shibata T, Niinobu T, Ogata N, Takami M (2000) Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 89(2):276–284CrossRefPubMed Shibata T, Niinobu T, Ogata N, Takami M (2000) Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 89(2):276–284CrossRefPubMed
14.
Zurück zum Zitat Hammill CW, Billingsley KG, Cassera MA, Wolf RF, Ujiki MB, Hansen PD (2011) Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol 18(7):1947–1954CrossRefPubMed Hammill CW, Billingsley KG, Cassera MA, Wolf RF, Ujiki MB, Hansen PD (2011) Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol 18(7):1947–1954CrossRefPubMed
15.
Zurück zum Zitat Nielsen K, van Tilborg AA, Meijerink MR et al (2013) Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg 37(6):1340–1347CrossRefPubMed Nielsen K, van Tilborg AA, Meijerink MR et al (2013) Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg 37(6):1340–1347CrossRefPubMed
16.
Zurück zum Zitat Tanis E, Nordlinger B, Mauer M et al (2014) Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 50(5):912–919CrossRefPubMed Tanis E, Nordlinger B, Mauer M et al (2014) Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 50(5):912–919CrossRefPubMed
17.
Zurück zum Zitat Gillams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19(5):1206–1213CrossRefPubMed Gillams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19(5):1206–1213CrossRefPubMed
18.
Zurück zum Zitat Kim KH, Yoon YS, Yu CS et al (2011) Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc 81(1):25–34CrossRefPubMedPubMedCentral Kim KH, Yoon YS, Yu CS et al (2011) Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc 81(1):25–34CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Ruers T, Punt C, Van Coevorden F et al (2012) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23(10):2619–2626CrossRefPubMedPubMedCentral Ruers T, Punt C, Van Coevorden F et al (2012) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23(10):2619–2626CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Ruers TPC, van Coevorden F et al (2015) Radiofrequency ablation combined with chemotherapy for unresectable colorectal liver metastases: Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 33(suppl):abstr 3501 Ruers TPC, van Coevorden F et al (2015) Radiofrequency ablation combined with chemotherapy for unresectable colorectal liver metastases: Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 33(suppl):abstr 3501
21.
Zurück zum Zitat Mahnken AH, Pereira PL, de Baere T (2013) Interventional oncologic approaches to liver metastases. Radiology 266(2):407–430CrossRefPubMed Mahnken AH, Pereira PL, de Baere T (2013) Interventional oncologic approaches to liver metastases. Radiology 266(2):407–430CrossRefPubMed
22.
Zurück zum Zitat European Association for the Study of the Liver, European Organisation for Research, Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48(5):599–641CrossRef European Association for the Study of the Liver, European Organisation for Research, Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48(5):599–641CrossRef
23.
Zurück zum Zitat Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52CrossRefPubMed Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52CrossRefPubMed
24.
Zurück zum Zitat Akinwande O, Scoggins C, Martin RC (2016) Early experience with 70–150 mum Irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. Anticancer Res 36(7):3413–3418PubMed Akinwande O, Scoggins C, Martin RC (2016) Early experience with 70–150 mum Irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. Anticancer Res 36(7):3413–3418PubMed
25.
Zurück zum Zitat Jones RP, Malik HZ, Fenwick SW et al (2016) PARAGON II – A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol 41(12):1866. doi:10.1016/j.ejso.2016.07.142 CrossRef Jones RP, Malik HZ, Fenwick SW et al (2016) PARAGON II – A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol 41(12):1866. doi:10.​1016/​j.​ejso.​2016.​07.​142 CrossRef
26.
Zurück zum Zitat Venturini M, Sallemi C, Agostini G et al (2016) Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study. Br J Radiol 89(1067):20160247CrossRefPubMed Venturini M, Sallemi C, Agostini G et al (2016) Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study. Br J Radiol 89(1067):20160247CrossRefPubMed
27.
Zurück zum Zitat Fiorentini G, Aliberti C, Benea G et al (2008) TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 55(88):2077–2082PubMed Fiorentini G, Aliberti C, Benea G et al (2008) TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 55(88):2077–2082PubMed
28.
Zurück zum Zitat Martin RC, Joshi J, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18(1):192–198CrossRefPubMed Martin RC, Joshi J, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18(1):192–198CrossRefPubMed
29.
Zurück zum Zitat de Baere T, Plotkin S, Yu R, Sutter A, Wu Y, Cruise GM (2016) An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol 27(9):1425–1431CrossRefPubMed de Baere T, Plotkin S, Yu R, Sutter A, Wu Y, Cruise GM (2016) An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol 27(9):1425–1431CrossRefPubMed
30.
Zurück zum Zitat Pereira PL, Plotkin S, Yu R et al (2016) An in-vitro evaluation of three types of drug-eluting microspheres loaded with irinotecan. Anticancer Drugs 27(9):873–878CrossRefPubMed Pereira PL, Plotkin S, Yu R et al (2016) An in-vitro evaluation of three types of drug-eluting microspheres loaded with irinotecan. Anticancer Drugs 27(9):873–878CrossRefPubMed
31.
Zurück zum Zitat Bower M, Metzger T, Robbins K et al (2010) Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford) 12(1):31–36CrossRef Bower M, Metzger T, Robbins K et al (2010) Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford) 12(1):31–36CrossRef
32.
Zurück zum Zitat Fiorentini G, Aliberti C, Tilli M et al (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32(4):1387–1395PubMed Fiorentini G, Aliberti C, Tilli M et al (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32(4):1387–1395PubMed
33.
Zurück zum Zitat Bhutiani N, Akinwande O, Martin RC 2nd (2016) Efficacy and toxicity of hepatic intra-arterial drug-eluting (Irinotecan) bead (DEBIRI) therapy in Irinotecan-refractory unresectable colorectal liver metastases. World J Surg 40(5):1178–1190CrossRefPubMed Bhutiani N, Akinwande O, Martin RC 2nd (2016) Efficacy and toxicity of hepatic intra-arterial drug-eluting (Irinotecan) bead (DEBIRI) therapy in Irinotecan-refractory unresectable colorectal liver metastases. World J Surg 40(5):1178–1190CrossRefPubMed
34.
Zurück zum Zitat Akinwande OK, Philips P, Duras P, Pluntke S, Scoggins C, Martin RC (2015) Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. Cardiovasc Intervent Radiol 38(2):361–371CrossRefPubMed Akinwande OK, Philips P, Duras P, Pluntke S, Scoggins C, Martin RC (2015) Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. Cardiovasc Intervent Radiol 38(2):361–371CrossRefPubMed
35.
Zurück zum Zitat Memon K, Lewandowski RJ, Riaz A, Salem R (2012) Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies. Curr Treat Options Oncol 13(3):403–415CrossRefPubMed Memon K, Lewandowski RJ, Riaz A, Salem R (2012) Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies. Curr Treat Options Oncol 13(3):403–415CrossRefPubMed
36.
Zurück zum Zitat Martin RC, Howard J, Tomalty D et al (2010) Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 33(5):960–966CrossRefPubMed Martin RC, Howard J, Tomalty D et al (2010) Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 33(5):960–966CrossRefPubMed
37.
Zurück zum Zitat Ariel IM (1965) Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Ann Surg 162:267–278CrossRefPubMedPubMedCentral Ariel IM (1965) Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Ann Surg 162:267–278CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Wollner I, Knutsen C, Smith P et al (1988) Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer 61(7):1336–1344CrossRefPubMed Wollner I, Knutsen C, Smith P et al (1988) Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer 61(7):1336–1344CrossRefPubMed
39.
Zurück zum Zitat Wollner IS, Knutsen CA, Ullrich KA et al (1987) Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs. Cancer Res 47(12):3285–3290PubMed Wollner IS, Knutsen CA, Ullrich KA et al (1987) Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs. Cancer Res 47(12):3285–3290PubMed
40.
Zurück zum Zitat Lau WY, Kennedy AS, Kim YH et al (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82(1):401–407CrossRefPubMed Lau WY, Kennedy AS, Kim YH et al (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82(1):401–407CrossRefPubMed
41.
Zurück zum Zitat Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12(12):1711–1720CrossRefPubMed Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12(12):1711–1720CrossRefPubMed
42.
Zurück zum Zitat Stubbs RS, Cannan RJ, Mitchell AW (2001) Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 5(3):294–302CrossRefPubMed Stubbs RS, Cannan RJ, Mitchell AW (2001) Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 5(3):294–302CrossRefPubMed
43.
Zurück zum Zitat Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88(2):78–85CrossRefPubMed Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88(2):78–85CrossRefPubMed
44.
Zurück zum Zitat Kennedy AS, Ball D, Cohen SJ et al (2015) Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol 6(2):134–142PubMedPubMedCentral Kennedy AS, Ball D, Cohen SJ et al (2015) Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol 6(2):134–142PubMedPubMedCentral
45.
Zurück zum Zitat Kennedy AS (2016) The role of radioembolization in colorectal cancer treatment. Expert Rev Anticancer Ther 16(4):375–376CrossRefPubMed Kennedy AS (2016) The role of radioembolization in colorectal cancer treatment. Expert Rev Anticancer Ther 16(4):375–376CrossRefPubMed
46.
Zurück zum Zitat Hendlisz A, Van den Eynde M, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28(23):3687–3694CrossRefPubMed Hendlisz A, Van den Eynde M, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28(23):3687–3694CrossRefPubMed
47.
Zurück zum Zitat Kennedy AS, Ball DS, Cohen SJ et al (2016) Safety and efficacy of radioembolization in elderly (>/= 70 years) and younger patients with unresectable liver-dominant colorectal cancer. Clin Colorectal Cancer 15(2):141–51 e6CrossRefPubMed Kennedy AS, Ball DS, Cohen SJ et al (2016) Safety and efficacy of radioembolization in elderly (>/= 70 years) and younger patients with unresectable liver-dominant colorectal cancer. Clin Colorectal Cancer 15(2):141–51 e6CrossRefPubMed
48.
Zurück zum Zitat Mulcahy MF, Lewandowski RJ, Ibrahim SM et al (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115(9):1849–1858CrossRefPubMed Mulcahy MF, Lewandowski RJ, Ibrahim SM et al (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115(9):1849–1858CrossRefPubMed
49.
Zurück zum Zitat Sangha BS, Nimeiri H, Hickey R, Salem R, Lewandowski RJ (2016) Radioembolization as a treatment strategy for metastatic colorectal cancer to the liver: what can we learn from the SIRFLOX trial? Curr Treat Options Oncol 17(6):26CrossRefPubMed Sangha BS, Nimeiri H, Hickey R, Salem R, Lewandowski RJ (2016) Radioembolization as a treatment strategy for metastatic colorectal cancer to the liver: what can we learn from the SIRFLOX trial? Curr Treat Options Oncol 17(6):26CrossRefPubMed
50.
Zurück zum Zitat Ayoola AO, Ibraheem AF (2016) SIRFLOX: progression-free survival in the liver as a surrogate end point for survival? J Clin Oncol 34(34):4193PubMed Ayoola AO, Ibraheem AF (2016) SIRFLOX: progression-free survival in the liver as a surrogate end point for survival? J Clin Oncol 34(34):4193PubMed
51.
Zurück zum Zitat Sag AA, Selcukbiricik F, Mandel NM (2016) Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol 22(11):3127–3149CrossRefPubMedPubMedCentral Sag AA, Selcukbiricik F, Mandel NM (2016) Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol 22(11):3127–3149CrossRefPubMedPubMedCentral
Metadaten
Titel
Lebermetastasen kolorektaler Karzinome
verfasst von
Prof. Dr. R.‑T. Hoffmann, MBA, EBIR
Publikationsdatum
27.01.2017
Verlag
Springer Medizin
Erschienen in
Die Radiologie / Ausgabe 2/2017
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI
https://doi.org/10.1007/s00117-017-0208-0

Weitere Artikel der Ausgabe 2/2017

Der Radiologe 2/2017 Zur Ausgabe

Mitteilungen des Berufsverbandes der Deutschen Radiologen

Mitteilungen des Berufsverbandes der Deutschen Radiologen

Passend zum Thema

ANZEIGE

Synergien nutzen gegen Tumore

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

ANZEIGE

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

ANZEIGE

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! PP-RB-DE-2009

Passend zum Thema

ANZEIGE

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

ANZEIGE

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

ANZEIGE

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

LEO Pharma GmbH